Merck KGaA keeps US tariff surcharge while pausing China fees; cuts sales guidance to €20.9-22.4B amid economic uncertainty.

Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Jiang­su Hen­grui, a 55-year-old drug­mak­er that has be­come one of Chi­na’s lead­ing forces in biotech, ex­pects net pro­ceeds of about 9.4 bil­lion Hong Kong dol­lars … ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...